Sumatriptan subcutaneous injection, FDA-approved since 1992, remains the fastest-acting migraine drug available — with relief beginning as early as 10 minutes after a single 6 mg dose under the skin. For the roughly 39 million Americans living with migraine, many of whom also navigate overlapping neurological concerns like cognitive decline and dementia risk, that speed matters. When a migraine hits hard enough to cause vomiting or visual disturbance, swallowing a pill is not always realistic. An injectable that works in under 30 minutes can mean the difference between a lost day and a recovered afternoon.
But sumatriptan is not the only injectable changing the migraine landscape. Vyepti (eptinezumab-jjmr), an intravenous infusion administered over 30 minutes just four times a year, represents a fundamentally different approach — prevention rather than rescue. Approved by the FDA in February 2020, it is the only IV-delivered CGRP monoclonal antibody for migraine prevention, and clinical data shows it can reduce migraine likelihood by more than 50% within the first 24 hours after infusion. This article covers how both drugs work, who they are best suited for, their limitations and costs, and what a new class of injectable treatments on the horizon could mean for people managing brain health alongside chronic migraine.
Table of Contents
- How Does an Injectable Migraine Drug Deliver Relief in 30 Minutes or Less?
- Vyepti — The 30-Minute IV Infusion That Prevents Migraines Before They Start
- What CGRP Drugs Mean for Brain Health and Dementia-Related Migraine
- Comparing Your Options — Injection, Infusion, and Nasal Spray
- Side Effects, Cardiovascular Warnings, and Who Should Not Use These Drugs
- The Cost Question — Insurance, Assistance Programs, and Out-of-Pocket Reality
- What Is Coming Next — Anti-PACAP Therapy and the Future of Injectable Migraine Prevention
- Conclusion
- Frequently Asked Questions
How Does an Injectable Migraine Drug Deliver Relief in 30 Minutes or Less?
The answer comes down to how the body absorbs medication. Oral migraine drugs must survive the digestive tract before entering the bloodstream — a process that takes 30 to 90 minutes under ideal conditions and far longer when nausea or gastroparesis slows gastric motility, which is common during a migraine attack. Sumatriptan injected subcutaneously bypasses all of that. The drug enters the tissue just below the skin and reaches therapeutic blood levels within minutes. According to a Cochrane Review analyzing multiple clinical trials, 70% of patients achieve meaningful headache relief within one hour of a single 6 mg subcutaneous dose, and onset begins as early as 10 minutes post-injection. Sumatriptan works by binding to serotonin receptors — specifically the 5-HT1B and 5-HT1D subtypes. This constricts dilated blood vessels around the brain and blocks the transmission of pain signals along the trigeminal nerve, which is the primary pain pathway involved in migraine.
It does not prevent future attacks. It is purely a rescue treatment, designed to stop an attack that is already underway. The American Headache Society specifically recommends subcutaneous sumatriptan for patients with severe nausea or vomiting who cannot take oral medications, and for those who have tried oral triptans without adequate results. For comparison, oral sumatriptan tablets typically take 30 to 60 minutes to begin working, and even nasal spray formulations are slower than injection. The subcutaneous route is, by a clear margin, the fastest triptan delivery method available. That said, speed comes with tradeoffs — injection site reactions are common, and many patients experience what are called “triptan sensations,” including transient chest tightness, tingling, and flushing. These side effects are generally not dangerous, but they can be alarming for someone experiencing them for the first time.
Vyepti — The 30-Minute IV Infusion That Prevents Migraines Before They Start
While sumatriptan stops a migraine in progress, Vyepti (eptinezumab-jjmr) aims to prevent attacks from occurring at all. Administered as a 30-minute intravenous infusion in a clinical setting every three months, it is the only CGRP monoclonal antibody delivered by IV. Because the entire dose enters the bloodstream directly during infusion, peak drug concentration is reached immediately at the end of that 30-minute session — no waiting days or weeks for the drug to build up, as is the case with self-injected CGRP antibodies like Aimovig or Ajovy. The clinical evidence is substantial. In the PROMISE-2 trial, which enrolled 1,050 patients with chronic migraine, Vyepti reduced monthly migraine days by 7.7 after 12 weeks of treatment. Even more striking is how quickly it works: on the first day after infusion, migraine rates were 27.8% to 28.6% among patients receiving the drug, compared to 42.3% in the placebo group. The SUNRISE trial showed similar results, with mean reductions of 7.5 monthly migraine days at the 300 mg dose and 7.2 days at the 100 mg dose, versus 4.8 days for placebo.
Patients were four times more likely to achieve a 75% or greater reduction in monthly migraine days compared to placebo within the first four weeks. However, Vyepti is not for everyone. It requires IV access in a healthcare facility, which means it is not something you can administer at home during an attack. It is a preventive, not a rescue drug. The most common side effects are nasopharyngitis (a fancy term for a common-cold-like irritation of the nose and throat) and hypersensitivity reactions. In clinical trials, the discontinuation rate due to adverse events was 1.9%, which is relatively low. But for patients who have had allergic reactions to monoclonal antibodies or who have limited access to infusion centers, Vyepti may not be practical.
What CGRP Drugs Mean for Brain Health and Dementia-Related Migraine
The intersection of migraine and dementia is not coincidental. Research has consistently shown that people with a history of migraine — particularly migraine with aura — carry a modestly elevated risk of cognitive decline and vascular dementia later in life. The reasons are not fully settled, but repeated episodes of cortical spreading depression (the wave of brain activity thought to underlie aura) and chronic neuroinflammation are leading theories. CGRP, the protein that Vyepti and other CGRP-targeting drugs block, plays a role in both migraine pain signaling and broader neuroinflammatory processes. This raises an interesting question for patients and caregivers managing both migraine and early cognitive concerns: could reducing migraine burden with a preventive like Vyepti also offer some degree of neuroprotective benefit? The honest answer is that we do not yet have long-term clinical data to confirm or deny this.
What we do know is that reducing the frequency and severity of migraine attacks lowers cumulative exposure to the inflammatory and vascular stress that each attack produces. For a patient in their 50s or 60s who is experiencing both increasing migraine frequency and early signs of cognitive change, aggressive migraine prevention is not just about comfort — it is about reducing a known risk factor for further neurological decline. For caregivers of dementia patients who also suffer from migraines, injectable treatments carry a practical advantage worth noting. A person with moderate cognitive impairment may not reliably remember to take a daily oral preventive or may not communicate migraine symptoms clearly until an attack is severe. A quarterly infusion administered in a clinical setting removes the compliance variable entirely.
Comparing Your Options — Injection, Infusion, and Nasal Spray
Choosing between sumatriptan injection, Vyepti infusion, and newer alternatives like Zavzpret nasal spray depends on whether the goal is rescue or prevention, and on the practical realities of the patient’s life. Sumatriptan injection is the go-to for acute rescue when speed is paramount. It is available in auto-injector form, can be self-administered at home, and has more than three decades of safety data behind it. The limitation is that it treats attacks one at a time and does nothing to reduce their frequency. Vyepti, by contrast, is a preventive treatment — four infusions per year, administered in a clinical setting, designed to reduce the number of attacks a patient experiences. The tradeoff is cost and access.
Estimated annual costs range from $7,240 for the 100 mg dose to $21,720 for the 300 mg dose, though financial assistance is available through Vyepti Connect at 833-489-3784. Not every insurance plan covers CGRP therapies without prior authorization, and patients in rural areas may find infusion centers inconvenient. Then there is Zavzpret (zavegepant), which is worth mentioning even though it is a nasal spray rather than an injectable. This CGRP receptor antagonist, approved by the FDA for acute migraine treatment, demonstrated pain relief as early as 15 minutes post-dose and return to normal function at 30 minutes in clinical trials. For patients who want fast-acting acute relief but are uncomfortable with needles, Zavzpret occupies a useful middle ground. It does not match sumatriptan injection’s track record, but it avoids injection site reactions entirely and targets CGRP rather than serotonin — making it an option for patients who cannot use triptans due to cardiovascular risk factors.
Side Effects, Cardiovascular Warnings, and Who Should Not Use These Drugs
No migraine treatment is without risk, and the injectable options carry specific concerns that patients and caregivers should understand clearly. Sumatriptan, because it constricts blood vessels, is contraindicated in patients with a history of heart attack, stroke, peripheral vascular disease, or uncontrolled hypertension. It should not be used within 24 hours of another triptan or an ergotamine-based drug. For older adults — particularly those already managing cardiovascular risk factors common in dementia populations — this is a real limitation. A neurologist may need to perform a cardiovascular evaluation before prescribing sumatriptan to a patient over 65. Vyepti’s safety profile is different but not without concerns. Because it is a monoclonal antibody, hypersensitivity reactions are the primary risk.
These are uncommon but can be serious, and infusion must occur in a setting equipped to manage anaphylaxis. The 1.9% discontinuation rate in clinical trials due to adverse events is reassuring but not zero. Patients switching from self-injected CGRP antibodies to Vyepti should not assume the transition is seamless — the IV route delivers the full dose immediately rather than gradually, which can produce different side effect timing. A broader caution applies to all CGRP-targeting therapies: CGRP is not exclusively a pain molecule. It plays roles in wound healing, cardiovascular protection, and gut function. Long-term blockade of CGRP is still being studied, and the consequences of years or decades of sustained CGRP suppression are not yet fully characterized. For patients who respond well and experience significant quality-of-life improvements, the benefit-risk calculation is generally favorable. But these drugs should not be treated as casual interventions, particularly in patients with complex medical histories.
The Cost Question — Insurance, Assistance Programs, and Out-of-Pocket Reality
Cost is one of the most common barriers to accessing injectable migraine therapies. Generic sumatriptan injection is relatively affordable, with auto-injectors available for $30 to $100 per dose depending on insurance and pharmacy. But Vyepti, as a newer biologic administered in an infusion center, is in a different financial category entirely. At $7,240 to $21,720 per year depending on dose, it represents a significant expense even with insurance coverage.
Many commercial insurers require step therapy — meaning the patient must document failure of two or more oral preventives before Vyepti is approved. For patients who qualify, the Vyepti Connect program offers financial assistance that can substantially reduce out-of-pocket costs. Medicare Part B typically covers infusion-administered drugs, though copay amounts vary by plan. Patients and caregivers should ask their neurologist’s office about prior authorization requirements early in the process, as approval can take weeks and delays mean missed infusion windows.
What Is Coming Next — Anti-PACAP Therapy and the Future of Injectable Migraine Prevention
The migraine treatment pipeline is not standing still. In February 2026, Slate Medicines launched with $130 million in Series A funding to develop SLTE-1009, a subcutaneous anti-PACAP monoclonal antibody for migraine prevention. PACAP (pituitary adenylate cyclase-activating peptide) is a signaling molecule involved in migraine pathophysiology that operates through a different pathway than CGRP. The hope is that anti-PACAP therapy could help the estimated 30% to 40% of patients who do not respond adequately to CGRP-targeting drugs.
Phase 1 clinical trials are expected to begin in mid-2026, with investors including RA Capital Management, Forbion, and Foresite Capital backing the effort. If SLTE-1009 proves effective, it would represent the first entirely new biological pathway targeted for migraine prevention in over a decade. For patients and caregivers managing both migraine and neurodegenerative conditions, the prospect of additional treatment options — especially ones that might work where current drugs fall short — is worth watching closely. The science of migraine treatment is moving faster now than at any point since sumatriptan first arrived in 1992, and injectable therapies remain at the center of that progress.
Conclusion
Injectable migraine treatments occupy two distinct but complementary roles. Sumatriptan subcutaneous injection remains the fastest rescue option available, with onset as early as 10 minutes and over 30 years of clinical use supporting its safety and efficacy. Vyepti, the only IV-administered CGRP preventive, offers a different kind of speed — quarterly 30-minute infusions that reduce migraine frequency by more than 50% within the first day and sustain that benefit for months.
Both drugs have real limitations, from cardiovascular contraindications to cost barriers, and neither is appropriate for every patient. For people navigating migraine alongside cognitive decline or dementia — whether as patients or caregivers — the key takeaway is that effective migraine management is a neurological priority, not just a comfort measure. Reducing migraine burden may lower cumulative neuroinflammatory exposure, and injectable options can simplify treatment for patients who struggle with daily oral medication adherence. Talk with a neurologist about which approach fits the specific clinical picture, ask about insurance coverage early, and keep an eye on emerging therapies like anti-PACAP antibodies that could expand the options within the next few years.
Frequently Asked Questions
How fast does sumatriptan injection actually work compared to pills?
Subcutaneous sumatriptan begins working as early as 10 minutes after injection, with 70% of patients achieving headache relief within one hour. Oral sumatriptan tablets typically take 30 to 60 minutes to begin working, and absorption is further delayed if the patient is experiencing nausea or vomiting during the attack.
Is Vyepti a treatment you take during a migraine attack?
No. Vyepti is a preventive treatment administered as a 30-minute IV infusion every three months in a healthcare facility. It is designed to reduce the number of migraine attacks over time, not to stop an attack that is already happening. For acute rescue during an attack, sumatriptan injection or Zavzpret nasal spray are the fast-acting options.
Can older adults with heart conditions use sumatriptan injection?
Sumatriptan is contraindicated in patients with a history of heart attack, stroke, peripheral vascular disease, or uncontrolled high blood pressure because it constricts blood vessels. Older adults, particularly those with cardiovascular risk factors common in dementia populations, should undergo cardiovascular evaluation before being prescribed sumatriptan. A neurologist may recommend alternative treatments like CGRP-based therapies that do not carry the same vascular risks.
How much does Vyepti cost per year?
Estimated annual costs range from $7,240 for the 100 mg dose to $21,720 for the 300 mg dose. Many insurance plans require prior authorization and documentation that oral preventives have failed before covering Vyepti. Financial assistance is available through the Vyepti Connect program at 833-489-3784, and Medicare Part B typically covers infusion-administered medications.
Are there migraine treatments targeting pathways other than CGRP?
Yes. Slate Medicines launched in February 2026 with $130 million in funding to develop SLTE-1009, a subcutaneous anti-PACAP monoclonal antibody. PACAP is a different signaling molecule involved in migraine, and targeting it could help the roughly 30% to 40% of patients who do not respond well to CGRP drugs. Phase 1 trials are expected to begin in mid-2026.
Is there a non-injectable option that works as fast as sumatriptan injection?
Zavzpret (zavegepant) nasal spray, a CGRP receptor antagonist approved by the FDA for acute migraine, demonstrated pain relief as early as 15 minutes and return to normal function at 30 minutes in clinical trials. It is not quite as fast as subcutaneous sumatriptan at its best, but it avoids needles entirely and works through a different mechanism, making it suitable for patients who cannot use triptans.
